ClinicalTrials.gg
Active, not recruitingNCT03063372Updated Apr 1, 2025

Pomegranate Supplementation and Well-Being Among Medical Students and Residents

An interventional study of Pomella pomegranate extract and Placebo in Antioxidant, Burnout, Professional and Psychological Distress, sponsored by University of Mississippi Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 21 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-01.

Sponsored by University of Mississippi Medical Center · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
21 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 97 studies in Burnout, Professional with a site in United States — 11 open to participants now, 16 under way, none of them phase 3. Burnout, Professional · United States.

Planned enrollment
60th of 90
50 · median 77
Started
2017
with 7 others
No phase
88 of 97
9 open now
Primary completion
2027-02
later than 6 of 15 live
Registered
9th of 97
by date

Among the 97 studies in Burnout, Professional with a site in United States, this one is the 60th largest by planned enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2017, is one of 88 with no phase, reaches primary completion later than 6 of the 15 other live ones, and was the 9th registered.

Burnout, Professional

218 studies on the registry are indexed under Burnout, Professional; 35 are open to participants now.

Browse Burnout, Professional studies →

Open to participants now

11 of the 97 studies in Burnout, Professional with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Burnout, Professional studies recruiting now, 9 (64%) set no upper age limit and 5 (36%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 21 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in Burnout, Professional with a site in United States, or all of them as a file.
02

Study summary

Medical students and residents have high rates of mental distress and burnout related to the intellectual and time demands of their training. Research shows that physiological stress on the body can be a result of fatigue and high stress work, and is associated with experiences related to mental distress. Pomegranate is a fruit that is known to contain a variety of antioxidant substances that can reduce physiological stress. This study will look at the potential for pomegranate supplementation to reduce physiological stress and improve well-being in medical students and residents.

Read the detailed description

This is a pilot study to investigate the feasibility of conducting a randomized trial of pomegranate supplementation in medical students and residents, and to see whether there is evidence of an effect on reported emotional and physical well-being.

Phase 1 will be a pilot with 10 participants in which all will receive the pomegranate supplement for 28 days. In phase 2, we will randomize 40 participants (1:1) to receive either the pomegranate supplement or a placebo.

For both phases, we will measure self reported emotional and physical well-being using several questionnaires, and we will conduct laboratory testing for measures of oxidative stress and inflammatory biomarkers in blood, and for a metabolite of pomegranate in urine.

03

Conditions studied

  • Antioxidant
  • Burnout, Professional
  • Psychological Distress

Keywords

  • Pomegranate
  • Burnout
  • Psychological Distress
  • Antioxidant
04

Who can participate

Ages eligible
21 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • First or second year medical student or first or second year resident listed at the University of Mississippi Medical Center

Exclusion criteria

Exclusion Criteria:

  • Pregnant or planning to become pregnant during the study period.
  • Breast feeding.
  • Unable to speak, understand, and read English.
  • Taking chronic medications other than
  • Taking supplements (including over-the-counter multivitamins)
  • Allergy to pomegranate or gelatin (gel-caps)
  • Baseline scores on the DASS-21 that indicate a level of depressive or anxiety symptoms that is "severe" or "extremely severe." This would be a depression score greater than 10, or an anxiety score greater than 7.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Pomegranate Supplement

    Participants in this arm will take a capsule with 500 mg of "Pomella" pomegranate extract twice each day for 28 days.

    Dietary Supplement: Pomella pomegranate extract

  • Placebo comparator
    Placebo

    Participants in this arm will take a gelatin placebo capsule twice each day for 28 days.

    Other: Placebo

Interventions

  • Dietary supplementPomella pomegranate extract

    Participants will take a 500 mg capsule of pomegranate extract twice daily for 28 days.

  • OtherPlacebo

    Participants will take a gelatin placebo twice daily for 28 days.

06

What researchers measure

Primary outcomes

  1. Changes in Scores on Maslach Burnout Inventory over time

    Survey instruments

    Time frame: baseline, 4 weeks , 8 weeks

  2. Changes in health as measured by scores on the RAND Short-Form 12 over time

    Survey instrument

    Time frame: baseline, 4 weeks , 8 weeks

  3. Changes in fatigue as measured by the Iowa Fatigue Scale over time

    Survey instrument

    Time frame: baseline, 4 weeks , 8 weeks

  4. Changes in mental health symptoms measured by the Depression/Anxiety/Stress Scale (21) over time

    Survey instrument

    Time frame: baseline, 4 weeks , 8 weeks

Secondary outcomes

  1. Change in Serum total antioxidant capacity over time

    Serum laboratory test

    Time frame: baseline, 4 weeks, 8 weeks

  2. Change in Th1 cytokine levels from peripheral blood and culture supernatants over time

    Immunologic tests

    Time frame: baseline, 4 weeks, 8 weeks

  3. Change in Th1 cytokine levels from peripheral blood and culture supernatants

    Immunologic test

    Time frame: baseline, 4 weeks, 8 weeks

  4. Change in Urinary Urolithins over time

    Urinary metabolite of pomegranate

    Time frame: baseline, 4 weeks, 8 weeks

  5. Change in serum total oxidative stress over time

    Serum laboratory test

    Time frame: baseline, 4 weeks, 8 weeks

  6. Change in Th2 cytokine levels from peripheral blood and culture supernatants over time

    Immunologic test

    Time frame: baseline, 4 weeks, 8 weeks

  7. Change in Th17 cytokine levels from peripheral blood and culture supernatants over time

    Immunologic test

    Time frame: baseline, 4 weeks, 8 weeks

  8. Change in TREG cytokine levels from peripheral blood and culture supernatants over time

    Immunologic test

    Time frame: baseline, 4 weeks, 8 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — We do not plan to share IPD.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2017 (actual). Primary completion is estimated for Feb 2027, 119 months after the start.

Of 128 non-industry interventional studies with no phase under Burnout, Professional, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 22. This study's planned 119 months is above that.

Counting every sponsor, half of 132 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2017
First posted
Feb 24, 2017
StartActual
Feb 28, 2017
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Apr 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03063372
Collaborators
University of Rhode Island
Responsible party
Joshua Mann (Professor, University of Mississippi Medical Center) — Principal investigator
First posted
Feb 24, 2017
Start date
Feb 28, 2017
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Apr 1, 2025

Study contacts

Joshua Mann, MD, MPH
principal investigator · University of Mississippi Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion